Preclinical Pharmacology of the Pyrrolobenzodiazepine (PBD) Monomer DRH-417 (NSC 709119)

References

• Wilson SC, Howard PW, Forrow SM et al. Design, syn-thesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2, 1-c][1,4]benzodiazepine system. J Med Chem 1999; 42: 4028–4041.
   Google Scholar
• Puvvada MS, Forrow SA, Hartley JA et al. Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1-c][1,4]benzodiazepines. Biochemistry 1997; 36: 2478–2484.
   Google Scholar
• Puvvada MS, Hartley JA, Jenkins TC et al. A quantita-tive assay to measure the relative DNA-binding affinity of pyrrolo[2,1-c] [1,4]benzodiazepine (PBD) antitumor antibiotics based on the inhibition of restriction endonuclease BamHI. Nucleic Acids Res 1993; 21: 3671–3675.
   Google Scholar
• Hisamatsu T, Uchida S, Tackeuchi T et al. Antitumor effect of a new antibiotic, neothramycin. Gann 1980; 71: 308–312.
   Google Scholar
• Kimura K, Ogawa M, Wakui A et al. Phase I study of a new antitumor antibiotic, neothramycin. Can To Kagaku Ryoho 1982; 9: 924–929.
   Google Scholar
• Tsugaya M, Washida H, Hirao N et al. The treatment of bladder cancer by neothramycin. Hinyokika Kiyo 1986; 32: 1443–1448.
   PubMedGoogle Scholar
• Baraldi PG, Cacciari B, Guiotto A et al. [2,1-c][1,4]ben-zodiazepine (PBD)-distamycin hybrid inhibits DNA binding to transcription factor Spl. Nucleosides Nucleotides Nucleic Acids 2000; 19: 1219–1229.
   PubMed Web of Science ®Google Scholar
• Black A, Black JD, Azizkhan-Clifford J. Spl and Krueppel-like factor family of transcription factors in cellgrowth regulation and cancer. J Cell Physiol 2001; 188: 143–160.
   PubMed Web of Science ®Google Scholar
• Smellie M., Bose DS, Thompson AS, et al. Sequence-selective recognition of duplex DNA through covalent inter-strand cross-linking: kinetic and molecular modeling studies with pyrrolobenzodiazepine dimmers. Biochemistry 2003; 42: 8232-8239.
   Google Scholar
• Wilkinson GP, Taylor JP, Shnyder S et al. Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent. Invest New Drugs 2004; 22: 231–240.
   Google Scholar
• No authors listed. Revolutionary cancer drug: targets cancer cells, ignores healthy ones. Coalition for medical progress, 27.05.2004 http://www.medicalprogress.org/refer-ence/news.cfm?newsid=109).
   Google Scholar
• Hartley JA, Spanswick V J, Brooks N et al. SJG-136(NSC 694501), a novel rationally designed DNA minor groove intrstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 1: Cellular pharmacology, in vitro and initial in vivo activity. Cancer Res 2004; 64: 6693–6699.
   Google Scholar
• Alley MC, Hollingshead MG, Pacula-Cox CM et al. SJG-136 (NSC 694501), A novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2:Efficacy evaluations. Cancer Res 2004; 64: 6700–6706.
   Google Scholar
• Dengler WA, Schulte J, Berger DP et al. Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. Anticancer Drugs 1995; 6: 522–532.
   Google Scholar
• Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumor xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discov-ery. Eur J Cancer 2004; 40: 802–820.
   PubMed Web of Science ®Google Scholar
• Berger DP, Henss H, Winterhalter BR et al. The clono-genic assay with human tumor xenografts: evaluation, predic-tive value and application for drug screening. Ann Oncol 1990; 1: 333–341.
   Google Scholar
• Skehan P, Storeng R, Scudiero D et al. New colorimet-ric cytotoxicity assay for anticancer-drug screening. J Nat Cancer Inst 1990; 82: 1107–1112.
   PubMed Web of Science ®Google Scholar
• Hill SR, Pollard L, Bibby MC. Sequence dependent activity of 5-fluorouracil plus tauromustine in a transplantable well-differentiated murine colon adenocarcinoma. AnticancerRes 1992; 12: 2169-2176.
   Google Scholar
• Geran RI, Greenberg NH, MacDonald MM et al. Protocols for screening chemical agents and natural products against tumor and other biological systems. Cancer Chemother Rep 1972; 3: 1–103.
   Google Scholar
• Gibaldi M. Biopharmaceutics and clinical pharmacoki-netics. 3rd ed. Philadelphia, Pa: Lea & Febiger; 1984: 169-170.
   Google Scholar
• Tozer, RM. Absorption. Clinical Pharmacokinetics: Concepts and Applications 2nd ed. Philadelphia, Lea & Febiger, 1989, 113-130.
   Google Scholar
• Davies B, Morris T. Physiological parameters in labora-tory animals and humans. Pharm Res 1993; 10: 1093–1095.
   PubMed Web of Science ®Google Scholar
• Grosios K, Loadman PM, Swaine DJ et al. Combination chemotherapy with combretastatin A-4 phos-phate and 5-fluorouracil in an experimental murine colon ade-nocarcinoma. Anticancer Res 2000; 20: 229–230.
   Google Scholar
• Holwell SE, Cooper PA, Grosios K et al. Combretastatin A-1 Phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumors. Anticancer Res 2002; 22: 707–712.
   Google Scholar
• Kirwan IG, Loadman PM, Swaine DJ et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and Al phosphate. Clin Cancer Res 2004; 10: 1446-1453.26 Werner H, Roberts CT Jr, LeRoith D. The regulation of IGF-I receptor gene expression by positive and negative zinc-finger transcription factors. Adv Exp Med Biol 1993; 343: 91–103.
   Google Scholar
• Dorkin TJ, Robson CN, Neal DE. The molecular pathology of urological malignancies. J Pathol 1997; 183: 380–387.
   PubMed Web of Science ®Google Scholar
• Takebayashi Y, Pourquier P, Yoshida A et al. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Biochemistry 1999; 13: 7196–7201.
   Google Scholar
• Fayette J, Coquard IR, Alberti L et al. ET-473: a novel agent with activity in soft tissue sarcomas. Oncologist 2005; 10: 827–832.
   Google Scholar
• Nelson SM, Ferguson LR, Denny WA. DNA and the chromosome - varied targets for chemotherapy. Cell&Chrom 2004; 3: 1–26. http://www.cellandchromosome.com/con-tent/3/1/2.
   Google Scholar